Next Gen Meds in MAS, SJIA, NLRC4 mutation and related diseases
Friday 21st of October: 6 PM
to
Sunday 23rd of October: 3 PM
Mandarin Oriental,
Washington DC.
Quick Links
Focus
SJIA, MAS, Still’s Disease, NLRC4 mutation, MAS+ILD and related diseases. Goal is to identify next gen drug options for patients who are not controlled by current drugs.
Participants types:
- Prominent Scientists focused on diseases listed above
- Small group of parents of kids with diseases listed above
- Scientists or representatives from drug companies
- Regulators from USA and Europe
Conference Schedule & Reception
Day 0 | Oct 21th, Friday Informal get together in the evening Keynote talk: Eric Hoffman |
Day 1 | Oct 22nd, Saturday 8.30 am to 5.30 pm Patients panel: to understand patient perspective & need for next gen therapies
|
Day 2 | Oct 23rd, Sunday: 8.30 am to 3.00 pm Breakfast session with patients: Focus group & Round Tables by investigators
|
Video & Presentation
Speaker | Presentation Title | Video Link | Presentation Link |
---|---|---|---|
Dr. Hermine Brunner | What is SJIA and how is it different than other diseases? | Video | Presentation |
Dr. Esi Morgan | Leading Quality Improvements in Pediatric Rheumatology Care | N/A | Presentation |
Dr. Daniel Lovell | Current Clinical Trials in SJIA & MAS | Video | Presentation |
Dr. Grant Schulert | Research Updates in SJIA & MAS | Video | Presentation |
Dr. Alexei Grom | Macrophage Activation Syndrome in SJIA | Video | Presentation |
Dr. Jennifer Huggins | Treating new and refractory SJIA patients | Video | Presentation |
Parent Panel | Parents Panel Issues & Concerns of SJIA parents | Video | N/A |
Doctor Panel | SJIA Experts Answer Parent's Questions | Video | N/A |
Conference Organizers
Organized by the Systemic JIA Foundation, a privately funded foundation based in California. The foundation organizes conferences, conducts surveys, makes seed grants, working with researchers and parents to accelerate the search for a cure. This conference is inspired by drug-discovery conferences organized by other rare disease foundations which have successfully accelerated development of new therapies by bringing together patients, researchers, pharma and regulators.